CA II, a potential biomarker by proteomic analysis, exerts significant inhibitory effect on the growth of colorectal cancer cells

Zhou,Rui; Huang,Wenjun; Yao,Yuqin; Wang,Yuxi; Li,Ziqiang; Shao,Bin; Zhong,Jian; Tang,Minghai; Liang,Shufang; Zhao,Xia; Tong,Aiping; Yang,Jinliang

doi:10.3892/ijo.2013.1972

CA II, a potential biomarker by proteomic analysis, exerts significant inhibitory effect on the growth of colorectal cancer cells

Authors:
- Rui Zhou
- Wenjun Huang
- Yuqin Yao
- Yuxi Wang
- Ziqiang Li
- Bin Shao
- Jian Zhong
- Minghai Tang
- Shufang Liang
- Xia Zhao
- Aiping Tong
- Jinliang Yang
View Affiliations

Affiliations: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, P.R. China, Department of Electrophysiology, Institute of Cardiovasology, Luzhou Medical College, Luzhou, Sichuan 646000, P.R. China, Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu 610041, P.R. China
Published online on: May 31, 2013 https://doi.org/10.3892/ijo.2013.1972
Pages: 611-621

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the Western world, colorectal cancer (CRC) is the third most common cancer with poor prognosis. To identify the proteins and to elucidate the possible mechanisms involved in colorectal carcinogenesis, 2-DE coupled with MS/MS analysis were employed to compare the global protein profile between CRC and individual matched normal tissues from 8 CRC patients. Of 36 proteins identified, carbonic anhydrase II (CA II) was one of most significantly altered and its downregulation in CRC tissues was verified by RT-PCR, western blotting and immunohistochemistry methods, suggesting that CA II may serve as a potential biomarker for CRC diagnosis. To investigate the function and mechanisms of CA II in CRC, a stable SW480 colorectal cancer cell line overexpressing CA II was established. It was shown that overexpression of CA II remarkably suppressed tumor cell growth both in vitro and in vivo, which was in part interpreted by cell cycle arrest at G0/G1 and G2 phase. Further mechanism analysis revealed that the sensitivity of colorectal cancer cells to chemotherapy drugs could be increased by CA II overexpression. Taken together, these data suggest that CA II may be a potential biomarker for early diagnosis of CRC and the results may contribute to a better understanding of the molecular mechanism of CRC and colorectal cancer treatment.

View Figures

View References

1.	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics. CA Cancer J Clin. 58:71–96. 2008.
2.	Woolf SH: The best screening test for colorectal cancer - a personal choice. N Engl J Med. 343:1641–1643. 2000. View Article : Google Scholar : PubMed/NCBI
3.	Walsh JM and Terdiman JP: Colorectal cancer screening: scientific review. JAMA. 289:1288–1296. 2003. View Article : Google Scholar : PubMed/NCBI
4.	Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar
5.	Phizicky E, Bastiaens PI, Zhu H, Snyder M and Fields S: Protein analysis on a proteomic scale. Nature. 422:208–215. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Alessandro R, Belluco C and Kohn EC: Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery. Clin Colorectal Cancer. 4:396–402. 2005. View Article : Google Scholar : PubMed/NCBI
7.	Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA and Nelson RW: Population proteomics: the concept, attributes and potential for cancer biomarker research. Mol Cell Proteomics. 5:1811–1818. 2006. View Article : Google Scholar : PubMed/NCBI
8.	Tyers M and Mann M: From genomics to proteomics. Nature. 422:193–197. 2003. View Article : Google Scholar
9.	Tong A, Zhang H, Li Z, et al: Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid. Cancer Chemother Pharmacol. 61:791–802. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Dahan L, Sadok A, Formento JL, Seitz JF and Kovacic H: Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol. 158:610–620. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Gilmour KM: Perspectives on carbonic anhydrase. Comp Biochem Physiol A Mol Integr Physiol. 157:193–197. 2010. View Article : Google Scholar : PubMed/NCBI
12.	Yoshiura K, Nakaoka T, Nishishita T, et al: Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod Pathol. 23:743–750. 2010. View Article : Google Scholar
13.	Yoshiura K, Nakaoka T, Nishishita T, et al: Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. Clin Cancer Res. 11:8201–8207. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Haapasalo J, Nordfors K, Järvelä S, et al: Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy. Neurooncology. 9:308–313. 2007.PubMed/NCBI
15.	Korhonen K, Parkkila AK, Helen P, et al: Carbonic anhydrases in meningiomas: association of endothelial carbonic anhydrase II with aggressive tumor features. J Neurosurg. 111:472–477. 2009. View Article : Google Scholar : PubMed/NCBI
16.	Kivela AJ, Saarnio J, Karttunen TJ, et al: Differential expression of cytoplasmic carbonic anhydrases, CA I and II and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors. Dig Dis Sci. 46:2179–2186. 2001. View Article : Google Scholar
17.	Kummola L, Hämäläinen JM, Kivelä J, Kivelä AJ, Saarnio J, Karttunen T and Parkkila S: Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa. BMC Cancer. 5:412005. View Article : Google Scholar : PubMed/NCBI
18.	Niemelä AM, Hynninen P, Mecklin JP, et al: Carbonic anhydrase IX is highly expressed in hereditary nonpolyposis colorectal cancer. Cancer Epidemiol Biomarkers Prev. 16:1760–1766. 2007.PubMed/NCBI
19.	Parks SK, Chiche J and Pouyssegur J: pH control mechanisms of tumor survival and growth. J Cell Physiol. 226:299–308. 2011. View Article : Google Scholar : PubMed/NCBI
20.	Swietach P, Vaughan-Jones RD and Harris AL: Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 26:299–310. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Pastorekova S, Ratcliffe PJ and Pastorek J: Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia. BJU Int. 101:8–15. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Lv L, Li D, Zhao D, et al: Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell. 42:719–730. 2011. View Article : Google Scholar : PubMed/NCBI
23.	Harris I, McCracken S and Mak TW: PKM2: a gatekeeper between growth and survival. Cell Res. 22:447–449. 2012. View Article : Google Scholar : PubMed/NCBI
24.	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
25.	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelialmesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Mallory JC, Crudden G, Oliva A, Saunders C, Stromberg A and Craven RJ: A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. Mol Pharmacol. 68:1747–1756. 2005.PubMed/NCBI